Empowered Patient Podcast

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases.

@RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis

RevoloBio.com

Listen to the podcast here

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases.

@RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis

RevoloBio.com

Download the transcript here

Anthony Comfort, VP Product Management, VisiQuate reflects on how far science and technology have come in helping monitor the health of diabetics with a new understanding of chemical changes in the body as well as cognitive and behavioral aspects. With the change from manual monitoring blood glucose readings to continuous data streaming in real time, patients and endocrinologists are able to stitch together data from a variety of sources to come up with personalized plans. Applying AI-enabled models and working with payers, providers and medical device companies, the goal is to optimize outcomes for patients and reduce costs.

@VisiQuate #DigitalTransformation #AI #COVID19 #DiabetesManagement #DigitalHealth #precisionmedicine

VisiQuate.com

Listen to the podcast here

Anthony Comfort, VP Product Management, VisiQuate reflects on how far science and technology have come in helping monitor the health of diabetics with a new understanding of chemical changes in the body as well as cognitive and behavioral aspects. With the change from manual monitoring blood glucose readings to continuous data streaming in real time, patients and endocrinologists are able to stitch together data from a variety of sources to come up with personalized plans. Applying AI-enabled models and working with payers, providers and medical device companies, the goal is to optimize outcomes for patients and reduce costs.

@VisiQuate #DigitalTransformation #AI #COVID19 #DiabetesManagement #DigitalHealth #precisionmedicine

VisiQuate.com

Download the transcript here

Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.

@CastleBio #SkinCancer #Melanoma #SquamousCellCarcinoma #GenomicTesting #Dermatology

CastleBiosciences.com

Listen to the podcast here

Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.

@CastleBio #SkinCancer #Melanoma #SquamousCellCarcinoma #GenomicTesting #Dermatology

CastleBiosciences.com

Download the transcript here

Len May, CEO, EndoCanna Health is aggressively exploring the genes that are associated with metabolism of cannabinoids and aiming for a better understanding of the endocannabinoid system to guide the use of cannabis for a wide range of conditions and disorders. With an eye to the complexity of the cannabis plant, EndoCanna has developed a test to determine an individual's genotype and endocompatibility to identify possible drug interactions, adverse effects and benefits of an optimal ratio of cannabinoids and terpenes endo-aligned dosage.

#cannabis #EndocannabinoidSystem #endocompatibility #terpenes #cannabinoids #THC #CBD

EndoDNA.com

Listen to the podcast here

Len May, CEO, EndoCanna Health is aggressively exploring the genes that are associated with metabolism of cannabinoids and aiming for a better understanding of the endocannabinoid system to guide the use of cannabis for a wide range of conditions and disorders. With an eye to the complexity of the cannabis plant, EndoCanna has developed a test to determine an individual's genotype and endocompatibility to identify possible drug interactions, adverse effects and benefits of an optimal ratio of cannabinoids and terpenes endo-aligned dosage.

#cannabis #EndocannabinoidSystem #endocompatibility #terpenes #cannabinoids #THC #CBD

EndoDNA.com

Download the transcript

Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics and hallucinogenics. PsyBio biosynthesizes psilocybin and other psychoactive drugs from different plants and fungi from genetically-modified bacteria. Under the influence of an anxiogenic molecule in a controlled setting, early clinical trials are showing a change in consciousness and rewiring of the brain to be able to address issues such as depression, anxiety, PTSD and substance abuse.

#Psychedelics #Psilocybin #Hallucinogenics #neuropsychiatricdisorders #tryptamines #PTSD #depression

PsyBioLife.com

Listen to the podcast here

Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics and hallucinogenics. PsyBio biosynthesizes psilocybin and other psychoactive drugs from different plants and fungi from genetically-modified bacteria. Under the influence of an anxiogenic molecule in a controlled setting, early clinical trials are showing a change in consciousness and rewiring of the brain to be able to address issues such as depression, anxiety, PTSD and substance abuse.

#Psychedelics #Psilocybin #Hallucinogenics #neuropsychiatricdisorders #tryptamines #PTSD #depression

PsyBioLife.com

Download the transcript here